David R. Bauer
Lawyers
Filters
Gilead Sciences $4.3 billion acquisition of CymaBay Therapeutics
We are advising Gilead Sciences on the acquisition
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
Ankura Consulting Group acquisition of Lumeri
We are advising Ankura on the acquisition
Bridgepoint sale of a minority interest in Humanetics
We are advising Bridgepoint and Humanetics on the transaction
Immatics $201 million follow-on offering
We advised Immatics on the offering of shares
Alector $75 million stock offering
The common stock is listed on the Nasdaq Global Select Market
Roche $295 million acquisition of LumiraDx's point of care technology platform
We are advising Roche on the acquisition
OPKO Health $230 million convertible senior notes offering
The 3.75% convertible notes are due 2029
Olema Pharmaceuticals $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market